ArticleFrontiers in immunology2018
Microphysiologic Human Tissue Constructs Reproduce Autologous Age-Specific BCG and HBV Primary Immunization
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Engineered tissues and strategies to overcome challenges in drug development.Advanced drug delivery reviews · 2020Pooled it
- Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.Current HIV research · 2026Review
- Innovative micro physiological systems for vaccine development.Human vaccines & immunotherapeutics · 2025Review
- Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.Vaccine · 2025Article
- Vaccinology: Getting our modernization act together.The Journal of experimental medicine · 2025Article
- Methods integrating innate and adaptive immune responses in humanFrontiers in immunology · 2025Review
- Article
- Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.The Journal of experimental medicine · 2024Article
- Modeling human immune responses to vaccination in vitro.Trends in immunology · 2024Review
- Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.NPJ vaccines · 2023Article
- A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.The Journal of infectious diseases · 2023Review
- The mRNA vaccine BNT162b2 demonstrates impaired TResearch square · 2022Article
- A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Precision Vaccine Adjuvants for Older Adults: A Scoping Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells.bioRxiv : the preprint server for biology · 2022Article
- Bacille Calmette-Guérin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro.Cell reports · 2022Article
- Human Blood Plasma Shapes Distinct Neonatal TLR-Mediated Dendritic Cell Activation via Expression of the MicroRNA Let-7g.ImmunoHorizons · 2021Article
- Precision Vaccine Development: Cues From Natural Immunity.Frontiers in immunology · 2021Review
- Human Newborn Monocytes Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and Metabolic ActivationFrontiers in immunology · 2021Article
- Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence.PLoS pathogens · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Current vaccine development disregards human immune ontogeny, relying on animal models to select vaccine candidates targeting human infants, who are at greatest risk of infection worldwide, and receive the largest number of vaccines. To help accelerate and de-risk development of early-life effective immunization, we engineered a human age-specific microphysiologic vascular-interstitial interphase, suitable for pre-clinical modeling of distinct age-targeted immunity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.